# A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Source: https://onco.cc/trials/nct05126719/  
OnCo record `nct05126719` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of MRG003, Capecitabine, Docetaxel in nasopharyngeal carcinoma, run by Lepu Biopharma Co., Ltd., active and no longer recruiting.

## Summary

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma is a phase 2 interventional study registered as NCT05126719 by Lepu Biopharma Co., Ltd., with 238 participants planned, started 2023-04-06 and due to reach its primary completion in 2024-12-30. Interventions recorded: MRG003, Capecitabine tablets, Docetaxel injection. Conditions listed: Recurrent or Metastatic Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05126719
- Phase: 2
- Setting: An Open-Label, Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
- Sponsor: Lepu Biopharma Co., Ltd.
- Enrolled: 238

## Sources

- ClinicalTrials.gov NCT05126719: https://clinicaltrials.gov/study/NCT05126719

## Connected records

- cancers: [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [MRG003](https://onco.cc/drugs/mrg003/)
- companies: [Lepu Biopharma](https://onco.cc/companies/lepu-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05126719.json